President-elect Trump is expected to get to work immediately upon taking office enacting major changes on immigration, energy and foreign policy. Trump late last year suggested he would not rule as a ...
Day One Biopharma's OJEMDA received FDA accelerated approval in 2024 for relapsed/refractory BRAF-altered pediatric low-grade glioma, with strong Phase 2 trial results and ongoing Phase 3 studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback